Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?
Alzheimer’s disease
Insulin resistance
Magnetic resonance imaging
Positron emission tomography imaging
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
17 02 2021
17 02 2021
Historique:
received:
14
11
2020
accepted:
03
02
2021
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
25
6
2021
Statut:
epublish
Résumé
Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated. Here we evaluated the influence of insulin resistance on brain glucose metabolism, grey matter volume and white matter lesions (WMLs) in non-diabetic AD subjects. In total, 130 non-diabetic AD subjects underwent MRI and [18F]FDG PET scans with arterial cannula insertion for radioactivity measurement. T1 Volumetric and FLAIR sequences were acquired on a 3-T MRI scanner. These subjects also had measurement of glucose and insulin levels after a 4-h fast on the same day of the scan. Insulin resistance was calculated by the updated homeostatic model assessment (HOMA2). For [18F]FDG analysis, cerebral glucose metabolic rate (rCMRGlc) parametric images were generated using spectral analysis with arterial plasma input function. In this non-diabetic AD population, HOMA2 was negatively associated with hippocampal rCMRGlc, along with total grey matter volumes. No significant correlation was observed between HOMA2, hippocampal volume and WMLs. In non-diabetic AD, peripheral insulin resistance is independently associated with reduced hippocampal glucose metabolism and with lower grey matter volume, suggesting that peripheral insulin resistance might influence AD pathology by its action on cerebral glucose metabolism and on neurodegeneration.
Sections du résumé
BACKGROUND
Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated. Here we evaluated the influence of insulin resistance on brain glucose metabolism, grey matter volume and white matter lesions (WMLs) in non-diabetic AD subjects.
METHODS
In total, 130 non-diabetic AD subjects underwent MRI and [18F]FDG PET scans with arterial cannula insertion for radioactivity measurement. T1 Volumetric and FLAIR sequences were acquired on a 3-T MRI scanner. These subjects also had measurement of glucose and insulin levels after a 4-h fast on the same day of the scan. Insulin resistance was calculated by the updated homeostatic model assessment (HOMA2). For [18F]FDG analysis, cerebral glucose metabolic rate (rCMRGlc) parametric images were generated using spectral analysis with arterial plasma input function.
RESULTS
In this non-diabetic AD population, HOMA2 was negatively associated with hippocampal rCMRGlc, along with total grey matter volumes. No significant correlation was observed between HOMA2, hippocampal volume and WMLs.
CONCLUSIONS
In non-diabetic AD, peripheral insulin resistance is independently associated with reduced hippocampal glucose metabolism and with lower grey matter volume, suggesting that peripheral insulin resistance might influence AD pathology by its action on cerebral glucose metabolism and on neurodegeneration.
Identifiants
pubmed: 33597002
doi: 10.1186/s13195-021-00784-w
pii: 10.1186/s13195-021-00784-w
pmc: PMC7890851
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Références
Neurology. 2008 Feb 5;70(6):440-8
pubmed: 17942819
Sci Transl Med. 2014 Mar 19;6(228):228fs13
pubmed: 24648338
Lancet Neurol. 2020 Sep;19(9):758-766
pubmed: 32730766
Diabetes. 1992 Jun;41(6):715-22
pubmed: 1587398
Lancet Neurol. 2020 Jul;19(7):582-590
pubmed: 32562683
Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25
pubmed: 15094078
J Alzheimers Dis. 2015;46(2):525-33
pubmed: 25812851
Nat Rev Neurol. 2018 Mar;14(3):168-181
pubmed: 29377010
J Alzheimers Dis. 2016 Apr 12;52(4):1373-83
pubmed: 27079723
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Biochim Biophys Acta. 2012 Mar;1822(3):333-9
pubmed: 21745566
Int J Mol Sci. 2016 Apr 05;17(4):503
pubmed: 27058526
Diabetes. 2014 Dec;63(12):4291-301
pubmed: 25008180
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Am J Physiol. 1989 Oct;257(4 Pt 1):E459-65
pubmed: 2679125
Diabetes Care. 2013 Dec;36(12):4036-42
pubmed: 23939539
Neurobiol Learn Mem. 2011 Oct;96(3):432-42
pubmed: 21907815
JAMA Neurol. 2015 Sep;72(9):1013-20
pubmed: 26214150
Diabetes. 2004 Feb;53(2):474-81
pubmed: 14747300
Neurology. 2015 Sep 29;85(13):1123-30
pubmed: 26333802
J Alzheimers Dis. 2015;45(4):1269-70
pubmed: 25869922
Alzheimers Res Ther. 2014 Jul 03;6(4):37
pubmed: 25024750
Lancet Neurol. 2011 Sep;10(9):819-28
pubmed: 21775213
Rev Neurosci. 2005;16(3):181-212
pubmed: 16323560
Diabetes Care. 2013 Feb;36(2):443-9
pubmed: 23069842
Eur J Pharmacol. 2004 Apr 19;490(1-3):97-113
pubmed: 15094077
Neurology. 2010 Nov 30;75(22):1982-7
pubmed: 21115952
Neurol Genet. 2020 Oct 6;6(5):e512
pubmed: 33225065
Diabetes. 2015 Jun;64(6):1933-40
pubmed: 25576061
Neurology. 2007 Feb 13;68(7):501-8
pubmed: 17065593
Compr Physiol. 2013 Jan;3(1):1-58
pubmed: 23720280
Geriatr Gerontol Int. 2015 Dec;15 Suppl 1:34-42
pubmed: 26671155
JAMA Neurol. 2020 Sep 1;77(9):1099-1109
pubmed: 32568367
Neurobiol Aging. 2011 Nov;32(11):1942-8
pubmed: 20031276
Diabetes. 1992 Jun;41(6):750-9
pubmed: 1587401
Front Neurosci. 2018 Nov 13;12:830
pubmed: 30542257
J Diabetes Res. 2017;2017:7420796
pubmed: 28656154
Metabolism. 2018 Jul;84:11-27
pubmed: 29195759
BMJ Open. 2018 Mar 23;8(3):e019362
pubmed: 29574441
J Aging Res. 2012;2012:384017
pubmed: 22500228
Trials. 2019 Apr 3;20(1):191
pubmed: 30944040
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
Alzheimers Res Ther. 2017 Apr 26;9(1):31
pubmed: 28441961
J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1329-31
pubmed: 22859390
Diabetes Care. 2017 Jun;40(6):751-758
pubmed: 28381479
Metab Brain Dis. 2017 Jun;32(3):799-810
pubmed: 28229380
Hum Brain Mapp. 2017 Apr;38(4):1933-1940
pubmed: 28105773
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Metab Brain Dis. 2021 Jan;36(1):67-83
pubmed: 32986168
World J Diabetes. 2014 Apr 15;5(2):89-96
pubmed: 24765237
J Alzheimers Dis. 2008 Apr;13(3):323-31
pubmed: 18430999
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Int J Cardiol. 2010 Aug 20;143(2):184-91
pubmed: 19261342
Int J Geriatr Psychiatry. 2015 Jun;30(6):551-7
pubmed: 25060738
Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25
pubmed: 23307037
Neurosci Lett. 2003 Jul 10;345(1):21-4
pubmed: 12809979
Transl Res. 2017 May;183:26-40
pubmed: 28034760
Eur J Pharmacol. 2004 Apr 19;490(1-3):5-12
pubmed: 15094069
Diabetes Care. 2013 Aug;36(8):2324-30
pubmed: 23564921
Arch Neurol. 2011 Jan;68(1):51-7
pubmed: 20837822